This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by EVEN, C.
Right arrow Articles by DARDENNES, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by EVEN, C.
Right arrow Articles by DARDENNES, R. M.
The British Journal of Psychiatry (2000) 177: 47-51
© 2000 The Royal College of Psychiatrists

Critical approach to antidepressant trials

Blindness protection is necessary, feasible and measurable

CHRISTIAN EVEN, MD, ERYC SIOBUD-DOROCANT, MD and ROLAND M. DARDENNES, MD

Clinique des Maladies Mentales et de l'Encéphale, Centre Hospitalier Sainte-Anne, Paris, France

Correspondence: Dr C. Even, Clinique des Maladies Mentales et de l'Encéphale, Centre Hospitalier Sainte-Anne, Paris, France

Declaration of interest None.

Background Double-blind placebo-controlled trials are the academic standard for clinical psychopharmacology research.

Aims To identify the potential defects of current double-blind procedures in trials involving antidepressants and to investigate whether safeguards for blindness protection are used.

Method We reviewed the literature and devised a short seven-item checklist for evaluating the quality of blindness protection. We performed a computerised search for 1998 to identify the placebo-controlled studies that evaluated the efficacy of an antidepressant. The checklist was used to assess all traceable antidepressant trials published in 1998.

Results Relevant criticisms question the blindness procedures. The available methods which may bolster blindness are very seldom used.

Conclusions Improvement in the blindness procedures used for antidepressant trials is necessary, feasible and measurable.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
J. MONCRIEFF
The antidepressant debate
The British Journal of Psychiatry, March 1, 2002; 180(3): 193 - 194.
[Full Text] [PDF]

Home page
 BMJHome page
C. Even, S. Friedman, and R. Dardennes
Antidepressant trials generally have methodological defects
BMJ, September 8, 2001; 323(7312): 574 - 574.
[Full Text]